Lu M, Pontecorvo MJ, Devous MD, et al. - Among patients with clinically diagnosed mild cognitive impairment (MCI) and dementia due to Alzheimer disease (AD), researchers sought to assess the connection between flortaucipir positron emission tomography (PET) visual interpretation and patients’ near-term clinical progression. Study 1 screened 298 patients and registered 160 candidates who had a flortaucipir scan at baseline visit. Study 2 selected 205 candidates from the AMARANTH trial, which was terminated after futility analysis. In this analysis of two open-label clinical trials, visual read of an advanced flortaucipir PET AD pattern was linked to an increased risk of 18-month cognitive and functional decline compared with other scan patterns. Such findings indicate that flortaucipir PET scans, when interpreted with a US Food and Drug Administration–approved, clinically applicable visual interpretation method, may provide useful information about the risk of clinical deterioration over 18 months in patients with AD and MCI.